JPRN-UMIN000012636招募中未知
The efficacy of sorafenib administration prior to TACE against the patients with intermediate HCC refractory to TACE - The efficacy of sorafenib administration prior to TACE
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with contraindication for sorafenib
研究者
相似试验
尚未招募
不适用
Efficacy and Safety of Sorafenib in Previously treated Advanced Hepatocellular Carcinoma: SOPT studyNeoplasmsKCT0006739ational Cancer Center50
招募中
不适用
Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study)Hepatocellular carcinomaJPRN-UMIN000006475Kagoshima University Medical and Dental Hospital70
进行中（未招募）
不适用
Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial - BOOSTadvanced hepatocellular carcinoma with ChildPugh liver function class BMedDRA version: 9.1Level: LLTClassification code 10024720EUCTR2009-013870-42-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
尚未招募
不适用
Phase I dose escalation study with sorafenib in combination with sirolimus in patients with solid tumor.malignant solid tumors10027655NL-OMON30326niversitair Medisch Centrum Sint Radboud18
进行中（未招募）
1 期
Study to evalueta the activity and safety of sorafenib when used as second line of therapy after pazopanib in patients affected by metastatic renal cell carcinoma.MedDRA version: 16.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000777-38-ITFondazione IRCCS Istituto Nazionale dei Tumori44